文献速递精神分裂症与精神病性障碍

全基因组关联研究揭示Duffy-null基因型对氯氮平相关中性粒细胞减少评估的重要性

A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.
PubMed 文献 · Mol Psychiatry · 2019-01-15

该研究在552例具有非洲遗传背景的难治性精神分裂症患者中开展氯氮平治疗期间中性粒细胞水平的全基因组关联研究,发现两个全基因组显著位点与低中性粒细胞计数相关。最显著位点由ACKR1基因的rs2814778驱动,该位点C等位基因纯合者发生中性粒细胞减少并需停用氯氮平的风险显著增高。

要点

  • rs2814778(Duffy-null)C等位基因纯合与氯氮平治疗期间中性粒细胞减少及停药风险显著相关。
  • 该基因型或可作为药物基因组学检测,辅助氯氮平启动和持续管理决策。
  • 研究聚焦非洲遗传背景人群,填补该人群氯氮平相关中性粒细胞减少遗传基础空白。

核心结论

  • rs2814778(Duffy-null)基因型与氯氮平治疗期间中性粒细胞减少及停药风险显著相关,可能作为药物基因组学检测辅助临床决策。

研究设计与样本

  • 在552例具有稳健推断非洲遗传背景的难治性精神分裂症患者中开展氯氮平治疗期间中性粒细胞水平的全基因组关联研究。

主要发现

  • 两个全基因组显著位点与氯氮平治疗期间低中性粒细胞计数相关。
  • 最显著位点由rs2814778驱动(β = -0.9,P = 4.21 × 10-21),为ACKR1基因已知调控变异。
  • rs2814778 C等位基因纯合者发生中性粒细胞减少并需停用氯氮平的风险显著增高(OR = 20.4,P = 3.44 × 10-7)。

关键数值与推荐

  • rs2814778 C等位基因纯合者发生中性粒细胞减少并需停用氯氮平的OR = 20.4(P = 3.44 × 10-7)。
  • rs2814778与低中性粒细胞计数关联的β = -0.9(P = 4.21 × 10-21)。

临床怎么用

  • 在非洲遗传背景患者中,rs2814778基因型或可辅助氯氮平启动和持续管理决策,但需额外安全性研究确认。

局限性

  • 研究仅纳入非洲遗传背景个体,结果外推至其他人群需谨慎。
  • 基因型作为药物基因组学检测的临床应用潜力尚待额外安全性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals of African ancestry in the United States and Europe are at increased risk of developing schizophrenia and have poorer clinical outcomes. The antipsychotic clozapine, the only licensed medication for treatment-resistant schizophrenia, is under-prescribed and has high rates of discontinuation in individuals of African ancestry, due in part to increased rates of neutropenia. The genetic basis of lower neutrophil levels in those of African ancestry has not previously been investigated in the context of clozapine treatment. We sought to identify risk alleles in the first genome-wide association study of neutrophil levels during clozapine treatment, in 552 individuals with treatment-resistant schizophrenia and robustly inferred African genetic ancestry. Two genome-wide significant loci were associated with low neutrophil counts during clozapine treatment. The most significantly associated locus was driven by rs2814778 (β = -0.9, P = 4.21 × 10-21), a known regulatory variant in the atypical chemokine receptor 1 (ACKR1) gene. Individuals homozygous for the C allele at rs2814778 were significantly more likely to develop neutropenia and have to stop clozapine treatment (OR = 20.4, P = 3.44 × 10-7). This genotype, also termed "Duffy-null", has previously been shown to be associated with lower neutrophil levels in those of African ancestry. Our results indicate the relevance of the rs2814778 genotype for those taking clozapine and its potential as a pharmacogenetic test, dependent on the outcome of additional safety studies, to assist decision making in the initiation and on-going management of clozapine treatment.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Legge SE, Pardiñas AF, Helthuis M, et al. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry. 2019. PMID: 30647433. doi:10.1038/s41380-018-0335-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。